Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia

被引:71
作者
Bertolami, MC [1 ]
Faludi, AA [1 ]
Batlouni, M [1 ]
机构
[1] Inst Dante Pazzanese Cardiol Sao Paulo, Sao Paulo, Brazil
关键词
cholesterol; fermentation; LDL-cholesterol; milk; yogurt;
D O I
10.1038/sj.ejcn.1600683
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Objective: To verify the effects on the lipid profile of a product of fermented milk (Gaio(R)) in patients with mild to moderate primary hypercholesterolemia. Design: The study was prospective, randomized, double-blinded and placebo controlled, with a crossover design. Subjects: Thirty-two patients (21 women and 11 men) with ages ranging between 36 and 65 years old were included in the study. All of them were on a controlled diet for at least 8 weeks. Intervention: Patients began, after clinical and laboratory analysis, in a randomized and double-blind manner to take 200 g daily of Gaio(R) or its placebo. After 8 weeks blood was collected again for lipid profile evaluation and the crossover was made. After an additional 8 weeks blood was collected for another lipid profile determination Results: All patients included completed the study. Comparisons were made between means of lipid profile constituents after the placebo and active product periods. These showed significant mean reduction of 5.3% (P = 0.004) for total cholesterol, 6.15% (P = 0.012) for LDL-cholesterol and no significant variation for HDL-cholesterol and triglycerides. The majority of patients presented no variation or had a decrease in their total cholesterol level. However, during the active product period, three patients showed an increase in cholesterol level by more than 5%. Conclusion: The fermented milk (Gaio(R)) produced a small but statistically significant decrease in total and LDL-cholesterol mean. However, not all subjects seem to respond to the product, and a few subjects showed a cholesterol increment. Further investigations are necessary to clarify this aspect. Sponsorship: Vigor Company, Brazil sponsored the study.
引用
收藏
页码:97 / 101
页数:5
相关论文
共 15 条
[1]  
AGERBAEK M, 1995, EUR J CLIN NUTR, V49, P346
[2]  
BAZZARRE TL, 1983, NUTR REP INT, V28, P1225
[3]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[4]  
EICHHOLZER M, 1993, INT J VITAM NUTR RES, V63, P159
[5]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[6]  
GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015
[7]   RANGE OF SERUM-CHOLESTEROL VALUES IN THE POPULATION DEVELOPING CORONARY-ARTERY DISEASE [J].
KANNEL, WB .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (09) :C69-C77
[8]  
LOTUFO PA, 1996, REV SOC CARDIOL ESTA, V6, P541
[9]  
MARTIN MJ, 1986, LANCET, V2, P933
[10]  
*MISS SCI SYND, 1997, LAIT, V77, P321